Leukemia Screening via Aspergillus Flavus and EBV Induction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing leukemia, particularly acute lymphoblastic leukemia, are complex, require skilled personnel, and lack definitive laboratory tests for predisposition or early detection, making it difficult to identify susceptible individuals and predict disease occurrence.
Innovation Solution
The use of cell surface markers and enzyme-linked-immunosorbent serologic assay (ELISA) to detect leukemic potential by exposing peripheral blood mononuclear cells to specific proteins from Aspergillus flavus and Epstein-Barr virus, re-creating markers characteristic of acute lymphoblastic leukemia, allowing for the identification of individuals at risk.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional leukemia diagnosis methods are used, then diagnosis can be made, but the methods are complex and require skilled personnel
Solution Approach 1:
The patent extracts and identifies specific cell surface markers (CD10, CD19, CD34, CD117) that are characteristic of acute lymphoblastic leukemia. By focusing on these specific markers rather than performing comprehensive complex analyses, the diagnosis method becomes simpler while maintaining reliability through targeted detection of these definitive markers.
Solution Approach 2:
The patent creates a simplified diagnostic model by copying the essential diagnostic criteria from complex traditional methods. Instead of requiring complex multi-parameter analysis, the invention uses a streamlined approach that detects the same diagnostic information through a simpler assay format, making the method more accessible while preserving diagnostic accuracy.
2Measurement precision
If traditional leukemia diagnosis methods are used, then diagnosis can be made, but definitive laboratory tests for predisposition or early detection are lacking
Solution Approach 1:
The patent applies preliminary action by detecting cell surface markers before the development of full-blown leukemia. The method identifies predisposition to acute lymphoblastic leukemia by detecting characteristic markers in at-risk individuals, enabling early intervention before the disease fully manifests. This preliminary detection approach provides both precision for early stage identification and reliability for predicting disease occurrence.
3Measurement precision
If complex diagnosis methods are used, then accurate diagnosis can be achieved, but it is difficult to identify susceptible individuals and predict disease occurrence
Solution Approach 1:
The patent develops a universal screening method that can identify susceptible individuals across different populations. The cell surface marker detection assay serves multiple functions: it diagnoses established leukemia cases, identifies at-risk individuals before disease development, and can be applied to various patient populations. This multi-functional approach simplifies the screening process while maintaining high precision for identifying susceptible individuals.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the reliable detection of acute lymphoblastic leukemia in individuals, both those who have had the disease and those at risk, providing a potential tool for mass screening and understanding the etiology of leukemia.
Implementation Method 1
enzyme-linked-immunosorbent serologic assay (ELISA) to detect the potential for acute lymphoblastic leukemia
Implementation Method 2
exposing peripheral blood mononuclear cells to specific proteins from Aspergillus flavus and Epstein-Barr virus, re-creating markers characteristic of acute lymphoblastic leukemia
Data Source
AI summary
A diagnostic test is described using Aspergillus flavus fungal cultures, EBV or their combination to induce leukemic cell surface markers in mononuclear cells of former or current leukemia patients. Unlike aflotoxin, which indiscriminately induces leukemic transformation, the compositions used were specific to leukemia-predisposed patients, but not other cancers or normal controls. The test identifies survivors of ALL and can detect propensity for development of leukemia in susceptible individuals. An ELISA technique using the described fungal products or EBV and combination can detect individuals with history of leukemia and not controls. These findings have implications for the etiology of leukemias and lymphomas and use for mass screening, detection of susceptible individuals to leukemia and potential vaccination.